15:23 , Apr 13, 2018 |  BC Week In Review  |  Company News

Orchard gains GSK's rare disease gene therapy portfolio

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.). GSK will be eligible to receive undisclosed commercial milestones and royalties. The pharma will...
15:48 , Apr 12, 2018 |  BC Extra  |  Company News

Orchard gains GSK's rare disease gene therapy portfolio

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.). GSK will be eligible to receive undisclosed commercial milestones and royalties. The pharma will...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...